Crinetics Pharmaceuticals, Inc.
DE ˙ DB ˙ US22663K1079
27,79 € ↑0,30 (1,09%)
2026-06-04
CENA AKCJI
SecurityDE:6Z4 / Crinetics Pharmaceuticals, Inc.
InstitutionVanguard Group Inc
Latest Disclosed Ownership0 shares
Ownership 0.00%
Vanguard Group Inc ownership in 6Z4 / Crinetics Pharmaceuticals, Inc.

2026-03-26 - Vanguard Group Inc has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 0 shares of Crinetics Pharmaceuticals, Inc. (DE:6Z4). This represents 0.0 percent ownership of the company. In their previous filing dated 2025-04-07 , Vanguard Group Inc had reported owning 9,311,600 shares, indicating a decrease of -100.00 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2026-03-26 2026-03-26 13G/A 9,311,600 0 -100.00 0.00 -100.00
2025-04-07 2025-04-07 13G/A 9,089,391 9,311,600 2.44 10.00 2.04
2025-01-30 2025-01-30 13G/A 6,287,655 9,089,391 44.56 9.80 24.84
2024-11-12 2024-11-12 13G/A 6,287,655 6,287,655 0.00 7.85 0.00
2024-11-04 2024-11-04 13G/A 3,502,452 6,287,655 79.52 7.85 49.81
2024-02-13 2024-02-13 13G 3,502,452 5.24

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-01-29 2025-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 9,135,504 -34,625 -0.38 425,258 11.34 0.0062
2025-11-07 2025-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 9,170,129 -86,003 -0.93 381,936 43.47 0.0057
2025-08-11 2025-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 9,256,132 -55,468 -0.60 266,206 -14.76 0.0043
2025-05-09 2025-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 9,311,600 222,209 2.44 312,311 -32.80 0.0056
2025-02-11 2024-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 9,089,391 2,801,736 44.56 464,741 44.64 0.0081
2024-11-13 2024-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 6,287,655 1,773,177 39.28 321,299 58.90 0.0058
2024-08-13 2024-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 4,514,478 939,402 26.28 202,203 20.83 0.0039
2024-05-10 2024-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 3,575,076 72,624 2.07 167,349 34.29 0.0033
2024-03-11 2023-12-31 13F/A-1 CRINETICS PHARMACEUTICALS IN COM 22663K107 3,502,452 95,417 2.80 124,617 22.99 0.0027
2024-02-14 2023-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 3,502,452 95,417 124,617 0.0024
2023-12-18 2023-09-30 13F/A-1 CRINETICS PHARMACEUTICALS IN COM 22663K107 3,407,035 674,301 24.67 101,325 105.77 0.0025
2023-11-14 2023-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 3,407,035 674,301 101,325 0.0004
2023-08-14 2023-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 2,732,734 39,672 1.47 49,244 13.86 0.0012
2023-07-14 2023-03-31 13F/A-1 CRINETICS PHARMACEUTICALS IN COM 22663K107 2,693,062 306,675 12.85 43,251 -0.96 0.0011
2023-05-15 2023-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 2,693,062 306,675 43,251 0.0002
2023-02-10 2022-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 2,386,387 29,740 1.26 43,671 -5.65 0.0012
2022-11-14 2022-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 2,356,647 -87,867 -3.59 46,284 1.52 0.0014
2022-08-12 2022-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 2,444,514 345,201 16.44 45,590 -1.06 0.0013
2022-05-13 2022-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 2,099,313 2,415 0.12 46,079 -22.65 0.0011
2022-02-14 2021-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 2,096,898 421,017 25.12 59,572 68.87 0.0014
2021-11-12 2021-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 1,675,881 173,044 11.51 35,277 24.53 0.0009
2021-08-13 2021-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 1,502,837 338,920 29.12 28,328 59.28 0.0007
2021-05-14 2021-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 1,163,917 11,659 1.01 17,785 9.40 0.0005
2021-02-12 2020-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 1,152,258 71,160 6.58 16,257 -4.03 0.0005
2020-11-16 2020-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 1,081,098 62 0.01 16,940 -10.56 0.0006
2020-08-14 2020-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 1,081,036 572,819 112.71 18,941 153.53 0.0007
2020-05-15 2020-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 508,217 4,216 0.84 7,471 -40.92 0.0003
2020-02-14 2019-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 504,001 -100 -0.02 12,646 66.77 0.0004
2019-11-14 2019-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 504,101 -438 -0.09 7,583 -39.88 0.0003
2019-08-14 2019-06-30 13F CRINETICS PHARMACEUTICALS COM 22663K107 504,539 52,327 11.57 12,614 22.56 0.0005
2019-05-15 2019-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 452,212 179,489 65.81 10,292 25.83 0.0004
2019-02-14 2018-12-31 13F CRINETICS PHARMACEUTICALS COM 22663K107 272,723 24,800 10.00 8,179 15.15 0.0004
2018-12-13 2018-09-30 13F/A-2 CRINETICS PHARMACEUTICALS COM 22663K107 247,923 247,923 7,103 0.0003
2018-11-23 2018-09-30 13F/A-1 CRINETICS PHARMACEUTICALS COM 22663K107 247,923 0 7,103 0.0003
2018-11-14 2018-09-30 13F CRINETICS PHARMACEUTICALS COM 22663K107 247,923 7,103 0.0003
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.